Keytruda Quadruples 5-Year Cure Rate in Triple-Negative Breast Cancer: KEYNOTE-522 Update
Quick Facts
Why Is Triple-Negative Breast Cancer So Difficult to Treat?
Triple-negative breast cancer accounts for 10-15% of all breast cancers and is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. This means it cannot be treated with hormonal therapies (tamoxifen, aromatase inhibitors) or HER2-targeted agents (trastuzumab, pertuzumab) that have transformed outcomes in other breast cancer subtypes. TNBC disproportionately affects younger women, Black women, and BRCA1 mutation carriers, and historically had the worst prognosis of all breast cancer subtypes, with 5-year survival of approximately 77% for early-stage disease and only about 12% for metastatic disease.
The KEYNOTE-522 trial was the first Phase 3 study to test adding an immune checkpoint inhibitor to standard neoadjuvant chemotherapy for early TNBC. Pembrolizumab works by blocking PD-1, a protein that cancer cells exploit to evade immune detection, thereby unleashing the immune system to recognize and destroy tumor cells. TNBC, with its higher mutational burden and greater immune cell infiltration compared to other breast cancer subtypes, was hypothesized to be particularly responsive to immunotherapy.
What Do the Long-Term KEYNOTE-522 Results Show?
KEYNOTE-522 enrolled 1,174 patients with previously untreated stage II-III TNBC. Patients received 4 cycles of pembrolizumab plus chemotherapy followed by 4 cycles of pembrolizumab plus additional chemotherapy before surgery, then 9 cycles of adjuvant pembrolizumab after surgery (or matching placebo throughout). At long-term follow-up, event-free survival was approximately 81.2% with pembrolizumab versus 72.0% with placebo (HR 0.63, p<0.001), representing a 37% reduction in the risk of recurrence, second cancer, or death.
A key finding was the interaction between pathological complete response and long-term outcomes. Among patients who achieved pCR (no residual invasive cancer at surgery), 5-year event-free survival exceeded 90% in the pembrolizumab group. Since pembrolizumab significantly increased the pCR rate (64.8% vs 51.2%), more patients overall achieved this favorable outcome. Preliminary overall survival data also showed a trend toward improvement with pembrolizumab (approximately 86-87% vs 81-82% at 5 years). These results have solidified pembrolizumab plus chemotherapy as the new global standard of care for early-stage TNBC.
Frequently Asked Questions
Pembrolizumab plus chemotherapy is now the recommended standard neoadjuvant regimen for stage II-III TNBC in guidelines from the NCCN, ESMO, and ASCO. For stage I TNBC, the risk-benefit balance is less clear, and treatment is individualized based on tumor size and nodal status.
Pembrolizumab can cause immune-related adverse events including thyroid dysfunction (reported in approximately 15-20% of patients), skin reactions, colitis, and rarely pneumonitis or hepatitis. In KEYNOTE-522, serious immune-related events occurred in approximately 14% of the pembrolizumab group. Most are manageable with corticosteroids and monitoring.
References
- Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020;382(9):810-821.
- Schmid P, et al. Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2022;386(6):556-567.
- U.S. Food and Drug Administration. FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer. July 2021.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2025.